WHO STI Research Priority Setting Technical Advisory Group
A Technical Advisory Group (TAG) on STI Research Priority Setting, consisting of external experts, will contribute to the planning, development, and implementation of the research priority setting exercise.

Sexually transmitted infections (STIs) have a profound impact on sexual and reproductive health (SRH) worldwide. In 2020, an estimated 374 million new infections occurred globally with one of the 4 curable STIs: syphilis, chlamydia, gonorrhea, and trichomoniasis. [1] The Global Health Sector Strategy on STIs (2016-2021) sets out several guiding principles for ending the STI epidemic as a public health problem,[2] but many gaps in evidence limit available guidance and tools, and progress toward STI prevention and control has been slow.[3] As an updated global strategy is developed for the next decade, new research is essential to strengthen the evidence base for new and improved interventions and guidelines including, but not limited to: the epidemiology, risk factors, and consequences of STIs; development and evaluation of behavioral, biomedical, clinical, and programmatic STI interventions and strategies; and scaling up existing interventions.

WHO is undertaking an exercise to identify global and regional STI research priorities. The systematic priority setting approach will involve consultation with a wide range of global stakeholders. A Technical Advisory Group (TAG) on STI Research Priority Setting, consisting of external experts, will contribute to the planning, development, and implementation of the research priority setting exercise. The STI Research Priority Setting TAG will be expected to oversee the process and to consider and include perspectives across regions, gender, populations and socioeconomics.

In its capacity as an advisory body to WHO, the STI Research Priority Setting TAG shall have the following functions:

  1. Develop the priority setting framework (eg. clarify the objectives, context, scope, and focus areas of the process).
  2. Review and provide comments to WHO on the research priority setting process protocol and survey tools.
  3. Generate lists of national, regional and global STI experts and stakeholder groups to ensure a broad range of survey participants are reached during the priority setting process implementation.
  4. Participate in consolidating STI research questions solicited from stakeholder surveys.
  5. Ensure that the proposed criteria for scoring research questions will address the objectives of the exercise.
  6. Review analysis and results of ranking and systematic listing of priority research questions (with data management/statistical support).
  7. Contribute to the WHO finalization. publishing and dissemination of global STI research priorities. 

The STI Research Priority Setting TAG will meet with the WHO Secretariat throughout this process. In keeping with the requirements of the WHO Advisory Groups guidelines and the WHO Compliance, Risk Management and Ethics Office, we are posting online short biographies of the TAG members. The listed candidates have also submitted a Declaration of Interest form stating any conflict of interests. WHO has applied its internal processes to ensure that the performance of the above tasks by members of this group will be transparent and without any significant conflict of interests (academic, financial, or other) that could affect the credibility of the process. Nevertheless, WHO invites the general public to review the experts and stakeholders involved and provide feedback regarding any member deemed to have a significant conflict of interest with respect to the terms of reference for this group. Comments and feedbacks should be cordial and constructive, and sent to  [email protected].

Technical Advisory Group (TAG) Members

Professor Laith Abu-Raddad

Professor of Infectious Disease Epidemiology, Weill Cornell Medicine, Cornell University, Qatar

Dr Adeniyi Aderoba

MBBS, MSc., FWACS, FMCOG. Consultant obstetrician and gynaecologist with the regional government in Nigeria, United Kingdom

Dr Laura Bachmann

Chief Medical Officer Division of STD Prevention, U.S. Centers for Disease Control and Prevention, United States of America

Dr Xiang-Sheng Chen

Deputy Director, National Center for STD Control Professor, Institute of Dermatology Chinese Academy of Medical Sciences & Peking Union Medical College, China

Dr Tania Crucitti

Clinical biologist and infectious disease researcher, Madagascar

Dr Sheela Godbole

Senior scientist and Head of Epidemiology, Indian Council of Medical Research – National AIDS Research Institute ( ICMR-NARI), India

Dr Somesh Gupta

Professor of Dermatology & Venereology, All India Institute of Medical Sciences, New Delhi, India

Dr Naoko Ishikawa

Physician, Kawasaki Settlement Clinic, CFMD Tokyo, Japan

Dr Jeffrey D. Klausner

Clinical Professor of Medicine Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, United States of America

Professor Angelica Espinosa Miranda

Medical School at Universidade Federal do Espírito Santo (UFES), Ministério da Saúde, Brazil

Professor Victor Ocholla Omollo

Junior research scientist, Kenya Medical Research Institute (KEMRI), Kenya

Dr Jason Ong

Sexual Health physician, Head of HIV/STI economics and health preference research, Melbourne, Australia

Professor Remco Peters

HIV/STI clinician, epidemiologist and researcher, East London, South Africa

Professor Kate Seib

Research Leader & Associate Director (Research)Institute for Glycomics Griffith University, Australia

Tim Sladden

Public health professional (MPH, MSc), with forty years work experience in communicable disease research, surveillance, prevention and response, and promotion of good health and wellbeing, Australia

Dr Barbara Van Der Pol

Professor of Medicine & Public Health Director, STD Diagnostics Lab Director, UAB STD Clinical Research Organization University of Alabama, United States of America

Professor Peter White

Professor of Public Health Modelling, Department of Infectious Disease Epidemiology, Imperial College School of Public Health,, London, United Kingdom

NOTE: The TAG members are participating in the meetings on their individual capacity. Affiliations are presented only as a reference. The participation of experts in a WHO meeting does not imply that they are endorsed or recommended by the WHO nor does it create a binding relationship between the experts and WHO. The biographies have been provided by the experts themselves and are the sole responsibility of the individuals concerned. WHO is not responsible for the accuracy, veracity and completeness of the information provided. In accordance with WHO conflict of interest assessment policy, expert’s biographies are published for transparency purposes. Comments and perceptions are brought to the knowledge of WHO through the public notice and comment process. Comments sent to WHO are treated confidentially and their receipt will be acknowledged through a generic email notification to the sender. Please send any comments to the following email: [email protected]. WHO reserves the right to discuss information received through this process with the relevant expert with no attribution to the provider of such information. Upon review and assessment of the information received through this process, WHO, in its sole discretion, may take appropriate management of conflicts of interests in accordance with its policies. 

Publications

Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021

This report provides accountability for the 3 Global Health Sector Strategies (2016-2021) on HIV, Viral Hepatitis and the STIs. The report assesses the...

Progress report on HIV, viral hepatitis and sexually transmitted infections 2019

WHO is accountable for reporting back to the World Health Assembly on progress in implementing the Global health sector strategies on HIV, viral hepatitis...

Global health sector strategy on Sexually Transmitted Infections, 2016-2021

The strategy positions the health sector response to sexually transmitted infection epidemics as critical to the achievement of universal health coverage...